Economy

Repros Therapeutics Inc. (NASDAQ:RPRX) Signals 'Overbought' Based on Its RSI

Repros Therapeutics Inc. has been given an analysts' mean target of 5.5. (RPRX) escalated 64.8% and closed its last trading session at $0.53.

Looking into last 5 trades, the stock observed a return of nearly 65.63%. The company's market cap is $19.94 million. The company has 37.5 Million shares outstanding and 37.36 Million shares were floated in market. For the most recent quarter, quick ratio was 1.80, current ratio was 1.80, LT Debt/Equity ratio was - and Total Debt/Equity ratio stands at -, while Payout ratio is 0.

Repros Therapeutics Inc. (NASDAQ:RPRX) touched its 1-Year High price of $2.180 on 10/07/16 and its 1-Year Low price of $0.260 on 08/22/17. The company has experienced volume of 2,525,238 shares while on average the company has a capacity of trading 3.58M share. Looking further out we can see that the stock has moved -59.85% over the year to date. It sustained ROA (TTM) at -212.10%.

Equity Research firms now have a positive stance on shares of Fenix Parts, Inc. Its weekly performance showed upward trend of 65.63 percent. Its Average True Range (ATR) shows a figure of 0.05.

Liquidity ratios help investors to determine a company's ability to pay off its debts. The Beta for the stock stands at 0.38.

Repros Therapeutics Inc. (NASDAQ:RPRX) shares are moving 29.83% trading at $0.69 today.

In order to check on the sell-side rational, we can also take a peek at some technical indicators. The stock closing price is now trading upward to its 50 day moving average with change of 68.60%, escalated to its 20 day moving average with figure of 67.85% and behind its 200 day moving average with value -32.72%. Institutional owners hold 20.10% stake in the company while Insiders ownership held at 0.20%. The mean target price as estimated by the analysts for the company has been recorded at $91.11. The company beat the analyst EPS Estimate with the difference of $0.01.

EPS growth for the next 5 years is 27.9 percent. A stock that maintains a relatively stable price has low volatility. It indicates oversold and overbought price levels for a stock.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

A statistical measure of the dispersion of returns (volatility) for RPRX producing salvation in Investors mouth, it has week volatility of 30.97% and for the month booked as 14.87%.

Repros Therapeutics Inc. (NASDAQ:RPRX) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent.

The company last reported its quarterly results on Nov 13 BMO. Analysts have a mean recommendation of 2.00 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). The company now has a Return on Equity of 8.20% and Return on Investment of 5.70%.



Like this

Latest


10 October 2017
Multiple tornadoes believed to have caused damage northwest of Charlotte
American Red Cross officials estimate that 30 homes were damaged and have opened a shelter at South Caldwell High School. If you have any photos or video of Sunday's storm or the damage they caused, send them to fox46pix@foxtv.com.

10 October 2017
Horror crash: Four dead, eight injured north of Taupo
Alternative routes will be put in place shortly however there will be significant delays, so motorists are asked to delay travel. Peter Wilkinson from nearby business Taupo Quad Adventures said a member of the public is operating the detour for police.

10 October 2017
Myer is offering free shipping for Christmas
It's called Shipster and it's something the Australian market has been needing for a long time. Mr Balbin said about 60 million U.S. households have signed up for the Amazon Prime service.

10 October 2017
We've two accounts, one property overseas : Karti Chidambaram
The CBI responded by saying, " we have things to show- the jugglery of accounts and properties overseas . This is in clear contradiction to what Karti, had tol d the agency-that he had just one account.

10 October 2017
Odisha Likely To Witness Heavy Rain, With Depression Likely To Intensify
Landing of 47 in-bound flights and departure of about 35 flights was rescheduled and many flights were delayed, an official said. During this period, the system has moved further west-northwestwards and at present, it is seen close to Bankura .

10 October 2017
Cognizant Technology Solutions Corp (NASDAQ:CTSH) Institutional Investors Sentiment
WFG Advisors LP boosted its holdings in shares of Cognizant Technology Solutions Corporation by 46.4% during the 2nd quarter. On August 8 the company was upgraded from "Buy" to "Buy" and a price target of $85.00 was set in a report from Berenberg.

10 October 2017
Earnings Prediction Review: Becton, Dickinson and Company (BDX)
Wall Street is only getting more bullish on the stock, with 4 of analysts who cover XNCR having a buy-equivalent rating. The stock of Becton Dickinson and Co (NYSE:BDX) has "Buy" rating given on Tuesday, July 18 by Piper Jaffray.

10 October 2017
Dodgers lead the Diamondbacks 3-1, chase Greinke off in sixth inning
When the series shifts to Phoenix on Monday for Game 3 at Chase Field, the focus will turn to Greinke, a former Dodger. Now down 2-0, the Arizona Diamondbacks will need to win Monday night in order to keep the world series hopes alive.

10 October 2017
Indonesia to probe $1.4bn Standard Chartered Guernsey funds transferred to Singapore
An earlier report by Bloomberg said that regulators in Europe and Asia are also looking into the matter. In a statement late yesterday, the MAS confirmed it is investigating the Standard Chartered transfer.

10 October 2017
The Value of Synchronoss Technologies, Inc. (NASDAQ:SNCR) Underpriced or Overpriced?
Similarly, Price to cash flow ratio is another helpful ratio in determining a company's value. (NasdaqGS: SNCR ) has a Q.i. Shares of Synchronoss Technologies ( SNCR ) traded down 3.11% on Monday, reaching $13.71. (NasdaqGS: SNCR ) is 4.845098.



Recommended